Truist Securities Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $616
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Danielle Brill maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers the price target from $715 to $616.
Truist Securities analyst Danielle Brill maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers the price target from $715 to $616.